BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wahaib K, Beggs AE, Campbell H, Kodali L, Ford PD. Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma. Am J Health Syst Pharm 2016;73:441-50. [PMID: 27001985 DOI: 10.2146/ajhp150487] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Pessoa Rodrigues C, Herman JS, Herquel B, Valsecchi CIK, Stehle T, Grün D, Akhtar A. Temporal expression of MOF acetyltransferase primes transcription factor networks for erythroid fate. Sci Adv 2020;6:eaaz4815. [PMID: 32671208 DOI: 10.1126/sciadv.aaz4815] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Zhong L, Zhou S, Tong R, Shi J, Bai L, Zhu Y, Duan X, Liu W, Bao J, Su L, Peng Q. Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma. Invest New Drugs 2019;37:616-24. [DOI: 10.1007/s10637-018-0651-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
3 Harding T, Swanson J, Van Ness B. EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes. Oncotarget 2018;9:21930-42. [PMID: 29774113 DOI: 10.18632/oncotarget.25128] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
4 Zhu Y, Yuan T, Zhang Y, Shi J, Bai L, Duan X, Tong R, Zhong L. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma. Drug Des Devel Ther 2019;13:4321-30. [PMID: 31908417 DOI: 10.2147/DDDT.S211665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Alzrigat M, Jernberg-Wiklund H, Licht JD. Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity. Epigenomes 2018;2:16. [PMID: 30761216 DOI: 10.3390/epigenomes2030016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
6 Lee H, Lee J, Kumar S, Wu Y, Huangfu W, Lai M, Li Y, Huang H, Kuo F, Hsiao C, Cheng C, Yang C, Liou J. 3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity. European Journal of Medicinal Chemistry 2017;125:1268-78. [DOI: 10.1016/j.ejmech.2016.11.033] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
7 Morabito F, Voso MT, Hohaus S, Gentile M, Vigna E, Recchia AG, Iovino L, Benedetti E, Lo-Coco F, Galimberti S. Panobinostat for the treatment of acute myelogenous leukemia. Expert Opin Investig Drugs 2016;25:1117-31. [PMID: 27485472 DOI: 10.1080/13543784.2016.1216971] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
8 Lernoux M, Schnekenburger M, Dicato M, Diederich M. Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia. Biochem Pharmacol 2020;173:113698. [PMID: 31706847 DOI: 10.1016/j.bcp.2019.113698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Albadari N, Deng S, Li W. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opin Drug Discov 2019;14:667-82. [PMID: 31070059 DOI: 10.1080/17460441.2019.1613370] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 16.3] [Reference Citation Analysis]
10 Sun Y, Chen BR, Deshpande A. Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia. Front Oncol 2018;8:41. [PMID: 29527516 DOI: 10.3389/fonc.2018.00041] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
11 Cavallo F, Troglio F, Fagà G, Fancelli D, Shyti R, Trattaro S, Zanella M, D'Agostino G, Hughes JM, Cera MR, Pasi M, Gabriele M, Lazzarin M, Mihailovich M, Kooy F, Rosa A, Mercurio C, Varasi M, Testa G. High-throughput screening identifies histone deacetylase inhibitors that modulate GTF2I expression in 7q11.23 microduplication autism spectrum disorder patient-derived cortical neurons. Mol Autism 2020;11:88. [PMID: 33208191 DOI: 10.1186/s13229-020-00387-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
12 Liu W, Liang Y, Si X. Hydroxamic acid hybrids as the potential anticancer agents: An Overview. European Journal of Medicinal Chemistry 2020;205:112679. [DOI: 10.1016/j.ejmech.2020.112679] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Ai C, Kong L. CGPS: A machine learning-based approach integrating multiple gene set analysis tools for better prioritization of biologically relevant pathways. J Genet Genomics 2018;45:489-504. [PMID: 30292791 DOI: 10.1016/j.jgg.2018.08.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 12.0] [Reference Citation Analysis]
14 Baz RC, Zonder JA, Gasparetto C, Reu FJ, Strout V. Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma. Oncol Ther 2016;4:287-301. [PMID: 28261656 DOI: 10.1007/s40487-016-0034-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
15 Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, Gavriatopoulou M, Terpos E, Dimopoulos MA. Efficacy of Panobinostat for the Treatment of Multiple Myeloma. J Oncol 2020;2020:7131802. [PMID: 32411240 DOI: 10.1155/2020/7131802] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
16 Yao ZG, Li WH, Hua F, Cheng HX, Zhao MQ, Sun XC, Qin YJ, Li JM. LBH589 Inhibits Glioblastoma Growth and Angiogenesis Through Suppression of HIF-1α Expression. J Neuropathol Exp Neurol 2017;76:1000-7. [PMID: 29136455 DOI: 10.1093/jnen/nlx088] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
17 Su L, Wang S, Yuan T, Xie X, Fu X, Ji P, Zhong L, Liu W. Anti-oral Squamous Cell Carcinoma Effects of a Potent TAZ Inhibitor AR-42. J Cancer 2020;11:364-73. [PMID: 31897232 DOI: 10.7150/jca.32436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]